[
  {
    "ts": null,
    "headline": "Assessing AbbVie (ABBV) Valuation After HSBC Upgrade, Strong Earnings, and Dividend Hike",
    "summary": "AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly results, higher earnings guidance, and another dividend increase. See our latest analysis for AbbVie. Even with a softer 1 month share price return of 4.25 percent, AbbVie’s 24.45 percent year to date share price gain and 33.32 percent 1 year total shareholder return show momentum is still firmly building, helped by upbeat trial data, pipeline updates, and that fresh...",
    "url": "https://finnhub.io/api/news?id=17253ebf1dfd412ccb4a2332edbe6d829d05935041050d86cb0cd5f57cad5157",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765667624,
      "headline": "Assessing AbbVie (ABBV) Valuation After HSBC Upgrade, Strong Earnings, and Dividend Hike",
      "id": 137792159,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly results, higher earnings guidance, and another dividend increase. See our latest analysis for AbbVie. Even with a softer 1 month share price return of 4.25 percent, AbbVie’s 24.45 percent year to date share price gain and 33.32 percent 1 year total shareholder return show momentum is still firmly building, helped by upbeat trial data, pipeline updates, and that fresh...",
      "url": "https://finnhub.io/api/news?id=17253ebf1dfd412ccb4a2332edbe6d829d05935041050d86cb0cd5f57cad5157"
    }
  },
  {
    "ts": null,
    "headline": "My Top 3 Healthcare Stocks to Buy in 2026",
    "summary": "These habitual market beaters can pull it off again.",
    "url": "https://finnhub.io/api/news?id=d10e614919cfb302e2bf095e946f09df3cd7f5ebc3b03804b7186c8a20c5b313",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765655820,
      "headline": "My Top 3 Healthcare Stocks to Buy in 2026",
      "id": 137792093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These habitual market beaters can pull it off again.",
      "url": "https://finnhub.io/api/news?id=d10e614919cfb302e2bf095e946f09df3cd7f5ebc3b03804b7186c8a20c5b313"
    }
  },
  {
    "ts": null,
    "headline": "5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine",
    "summary": "Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. These five stocks deliver that combination, each offering distinct advantages for compounding wealth over time. #5: Procter & Gamble (PG): The Steady Compounder Procter & Gamble earns ... 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine",
    "url": "https://finnhub.io/api/news?id=fc561247fd62bd4b94117719b45b5f666483ccb5ebfcb46806cb9e2cea1d01e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765650407,
      "headline": "5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine",
      "id": 137792123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. These five stocks deliver that combination, each offering distinct advantages for compounding wealth over time. #5: Procter & Gamble (PG): The Steady Compounder Procter & Gamble earns ... 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine",
      "url": "https://finnhub.io/api/news?id=fc561247fd62bd4b94117719b45b5f666483ccb5ebfcb46806cb9e2cea1d01e3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Right Long-Term Strategy",
    "summary": "Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.",
    "url": "https://finnhub.io/api/news?id=7cbe803f884a8945aad6b83c6a9a2ce67e0afb8f38f6abe0065fab9acd887ad6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765600404,
      "headline": "Eli Lilly: The Right Long-Term Strategy",
      "id": 137774561,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1874681159/image_1874681159.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.",
      "url": "https://finnhub.io/api/news?id=7cbe803f884a8945aad6b83c6a9a2ce67e0afb8f38f6abe0065fab9acd887ad6"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains AbbVie (ABBV) Overweight Recommendation",
    "summary": "Morgan Stanley Maintains AbbVie (ABBV) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=4272698fa5ce018ae853f51e756288fa49bb7bad7304257d9c0ab9e7e7c4ee49",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765584425,
      "headline": "Morgan Stanley Maintains AbbVie (ABBV) Overweight Recommendation",
      "id": 137772404,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4272698fa5ce018ae853f51e756288fa49bb7bad7304257d9c0ab9e7e7c4ee49"
    }
  }
]